BCLI - brainstorm-cell.com Long-Term Liabilities to Capital

Brandmark of BrainStorm Cell Therapeutics Inc. (BCLI)

The daily price chart for Brainstorm Cell (BCLI), which currently stands at 0.00, is based on the neuron regeneration potential of the NurOwn platform. Drug approval will grant the company full pricing power due to the critical nature of the therapy. Business efficiency relies on the flawless transportation of biomaterials in liquid nitrogen. Stable development is guaranteed by a highly qualified staff of scientists retained through a stock option system.

BCLI - Brainstorm Cell Therapeutics Inc. Long-Term Debt to Equity over the range 07/04/2022 - 08/02/2025

Analytical breakdowns for Brainstorm Cell

- price and consensus price forecast:
Share Price Brainstorm Cell Therapeutics Inc.|BCLI - Analyst Consensus Forecast
- market capitalization data:
Market Value Brainstorm Cell Therapeutics Inc.|BCLI - Real Price to Acquire Entire Company
- book capitalization data:
Book Value per Share BrainStorm Cell Therapeutics|BCLI - Company Book Value|Market Value to Book Value brainstorm-cell.com|BCLI - Aggregate Company Assets
- debt and liquidity data:
Debt to Capital Brainstorm Cell|BCLI - Long-Term Debt to Capital|Short-Term Debt to Equity brainstorm-cell.com|BCLI - Company Debts|Debt to Net Assets Ratio Brainstorm Cell Therapeutics Inc.
Initial company analysis:BCLI, Brainstorm Cell Therapeutics Inc.
Core merchandise of brainstorm-cell.com

The metric is calculated as the ratio of liabilities with a maturity exceeding one year to the market value of equity. It determines the business's degree of dependence on external financing and its financial stability. For Brainstorm Cell (BCLI), such a debt structure supports diversified research and development in the field of neurodegenerative diseases. This mitigates regulatory risks by allocating resources across various programs. The trend in the long-term debt-to-equity ratio reflects the company's current level of financial leverage.

Key competitors

Long-Term Debt to Capital Ratio Biogen Inc|Neurocrine Biosciences Inc - Long-Term Debt to Capital|Long-Term Liabilities to Capital Regencell Corp RGC|Long-Term Debt to Equity Ratio AXSM (Axsome Therapeutics)|acadia-pharm.com - Long-Term Debt to Capital|Long-Term Debt to Equity Xenon (XENE)|VKTX: Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity SUPN|Catalyst Corp (CPRX) - Long-Term Liabilities to Capital|Long-Term Debt to Capital Denali Therapeutics|Long-Term Debt to Equity HRMY|Biohaven (BHVN) - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient Amylyx Pharmaceuticals Inc (AMLX)|Long-Term Debt to Capital TRVI (Trevi Pharma)|Long-Term Debt to Capital Praxis Corp PRAX|Long-Term Debt to Capital AVXL (Anavex Life Sciences)|CBLL: Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Prothena Corp|ALEC (Alector) - Long-Term Debt to Capital Ratio|ANNX: Long-Term Debt to Equity|Ratio of Long-Term Indebtedness to Capital Omeros Corp. (OMER)|Long-Term Debt to Equity Ratio Neurogene Inc.|Long-Term Loans to Capital Ratio ACIU (acimmune.com)|VYGR: Long-Term Debt to Equity|Neumora - Long-Term Liabilities to Capital|Long-Term Debt to Equity Scilex Holding Co. (SCLX)|TVGN: Long-Term Debt to Capital Coefficient|ACOG (alphacognition.com) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio cogrx.com|IKT - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient Cassava Sciences Inc|Long-Term Debt to Capital ASRT (Assertio Holdings, Inc.)|Long-Term Debt to Equity Ratio coyatherapeutics.com (COYA)|VTGN: Long-Term Debt to Capital|Ovid Therapeutics Inc - Long-Term Liabilities to Capital|ABOS - Long-Term Debt to Equity|CRVO: Long-Term Debt to Equity|alteritytherapeutics.com (ATHE) - Long-Term Debt to Equity|Clene (CLNN) - Long-Term Debt to Equity|Long-Term Debt to Capital PepGen Inc|Long-Term Debt to Equity jupiterneurosciences.com|Long-Term Debt to Capital RLMD (Relmada Therapeutics, Inc.)|Long-Term Debt to Equity Ratio ANVS (Annovis Bio Inc)|Long-Term Debt to Equity Grace Therapeutics GRCE|Long-Term Debt to Equity Firefly Neuro AIFF|Long-Term Debt to Capital KLTO (ANEW Medical, Inc.)|NRSN: Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Reviva Pharmaceuticals Holdings, Inc.|MetaVia (MTVA) - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital NRXS (NeurAxis, Inc)|Long-Term Liabilities to Capital Helius Medical Technologies Inc. (HSDT)|Long-Term Debt to Equity Ratio PASG|Long-Term Debt to Capital NEUP (bionomics.com.au)|Long-Term Debt to Equity Minerva Neurosciences, Inc.|Athira Pharma Inc - Long-Term Debt to Capital Coefficient|ADXN (Addex Therapeutics, Ltd.) - Long-Term Debt to Equity|ALZN - Long-Term Liabilities to Capital|cyclerion.com (CYCN) - Long-Term Debt to Capital|PTIX (Protagenic Therapeutics, Inc.) - Long-Term Debt to Equity|KTTA - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient Cortigent Medical|Long-Term Debt to Capital ATXI|Long-Term Debt to Capital Cara Therapeutics Inc (CARA)|Long-Term Debt to Capital CHRO|Eliem Therapeutics, Inc. - Ratio of Long-Term Indebtedness to Capital|Intra-Cellular (ITCI) - Long-Term Debt to Equity|LBPH: Long-Term Debt to Capital Ratio|Marinus - Long-Term Debt to Equity|Ratio of Long-Term Indebtedness to Capital NKGen Biotech Corp|NeuroBo Pharmaceuticals (NRBO) - Long-Term Debt to Equity Ratio|Long-Term Loans to Capital Ratio SAGE|Synaptogenix - Long-Term Debt to Equity|Long-Term Liabilities to Capital TRVN (Trevena Inc.)|Long-Term Debt to Equity Vigil Neuroscience, Inc.|Anew Medical Inc. - Long-Term Debt to Capital Coefficient|CERE: Long-Term Debt to Equity